Where can I buy the original research version of lorlatinib/lorlatinib in China?

Lorlatinib/ Lorlatinib ( Lorlatinib), originally developed by Pfizer (Pfizer), is a highly selective third-generation ALK/ROS1 inhibitor, known as "the last line of defense after ALK resistance." At present, the drug has been officially launched in mainland China under the trade name Lorlatinib Tablets. It is an imported version of the original research and has been included in the National Medical Insurance Category B Catalog, which has significantly reduced the financial burden on patients.

in the country, lorlatinib can be purchased through a variety of formal channels. First, patients can purchase it at the oncology department or related pharmacies of tertiary hospitals with a doctor’s prescription. Since lorlatinib is a prescription drug, it can only be prescribed after a doctor confirms the indications.

Currently, the original research version of lorlatinib available in China is mainly available in two specifications: 25 mg × 90 tablets and 100 mg × 30 tablets. The price per box is about RMB 20,000. The actual payment amount varies slightly according to local medical insurance policies. Patients in areas not covered by medical insurance or who pay for themselves can purchase it through authorized pharmacies, and the price is usually slightly higher. In contrast, the original version of lorlatinib in Hong Kong is relatively expensive, ranging from RMB 30,000 to RMB 50,000. Some patients purchase the drug through Hong Kong pharmacies or formal cross-border medical channels, but attention must be paid to channel qualifications and drug authenticity verification.

For some patients with non-small cell lung cancer who want long-term treatment guarantees, they can order original drugs through official domestic pharmacies. It is worth noting that some generic lorlatinib drugs produced by Laos or Bangladeshi pharmaceutical companies have appeared on the market, and their prices are generally low. Such products are used in some overseas markets.

Overall, the Chinese market has been able to stably supply the original version of lorlatinib, and patients can obtain safe and reliable sources of drugs through formal medical channels, prescription pharmacies and the medical insurance system. With the expansion of medical insurance coverage and the improvement of the supply chain, the accessibility of lorlatinib in China is gradually increasing, bringing more sustainable and higher-quality treatment options to ALK-positive lung cancer patients.

References：https://www.lorbrena.com/